Design, Synthesis, and Biological Evaluation of Novel Disubstituted Dibenzosuberones as Highly Potent and Selective Inhibitors of p38 Mitogen Activated Protein Kinase
- 15 June 2012
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 55 (12), 5868-5877
- https://doi.org/10.1021/jm300327h
Abstract
Synthesis, biological testing, structure-activity relationships (SARs), and selectivity of novel disubstituted dibenzosuberone derivatives as p38 MAP kinase inhibitors are described. Hydrophilic moieties were introduced at the 7-, 8-, and 9-position of the 2-phenylamino-dibenzosuberones, improving physicochemical properties as well as potency. Extremely potent inhibitors were obtained, with half-maximal inhibitory concentration (IC(50)) values in the low nM range in a whole blood assay measuring the inhibition of cytokine release. The high potency of the target compounds together with the outstanding selectivity of this novel class of compounds toward p38 mitogen activated protein (MAP) kinase as compared to other kinases indicate them to be most applicable as tools in pharmacological research and eventually they may foster a new generation of anti-inflammatory drugs.Keywords
This publication has 23 references indexed in Scilit:
- p38α mitogen-activated protein kinase inhibitors, a patent review (2005 – 2011)Expert Opinion on Therapeutic Patents, 2011
- Successful Structure-Based Design of Recent p38 MAP Kinase InhibitorsCurrent Topics in Medicinal Chemistry, 2009
- Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibitionExpert Opinion on Drug Discovery, 2008
- Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibitionExpert Opinion on Drug Discovery, 2008
- A quantitative analysis of kinase inhibitor selectivityNature Biotechnology, 2008
- MAP Kinase p38Inhibitors: Clinical Results and an Intimate Look at Their Interactions with p38α ProteinCurrent Medicinal Chemistry, 2005
- A small molecule–kinase interaction map for clinical kinase inhibitorsNature Biotechnology, 2005
- Pyrroles and other heterocycles as inhibitors of P38 kinaseBioorganic & Medicinal Chemistry Letters, 1998
- 1-Substituted 4-Aryl-5-pyridinylimidazoles: A New Class of Cytokine Suppressive Drugs with Low 5-Lipoxygenase and Cyclooxygenase Inhibitory PotencyJournal of Medicinal Chemistry, 1996
- A protein kinase involved in the regulation of inflammatory cytokine biosynthesisNature, 1994